EGFR and non-small cell lung carcinoma: Patient subgroup analysis in another Phase III trial (KEYNOTE-010) evaluating pembrolizumab (another PD-1 inhibitor) also indicated that EGFR mutant NSCLC did not achieve statistically significant OS benefit from immunotherapy over salvage chemotherapy (46).